Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for earnings, it missed the same for sales. Earnings of 92 cents per share rose 12 ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

The stock's fall snapped a four-day winning streak.

MRNA stock Vs. PFE stock YTD performance (as of 31 Aug 21). Therefore, with both companies having their fair share of success in the COVID-19 market, we are rather surprised (although as MRNA ...

In this note, we discuss Pfizer’s stock performance, key takeaways from its recent results, and valuation. PFE stock has seen a decline of 15% from levels of $35 in early January 2021 to around ...

Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade. Here's why they chose Abbott Laboratories ( ABT -1.00%), AbbVie ( ABBV 2.86%), ...

Firstly, let us look at Pfizer’s stock performance in recent years. PFE stock has faced a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 45% ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...